Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
Vimseltinib Romvimza 14mg, 20mg, 30mg Chemotherapy Tyrosine Kinase Inhibitor CSF1R Yes 2025 In Use
N/A Dordaviprone MODEYSO 125mg Chemotherapy Protease Activator ClpP, dopamine D2 Yes 2025 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
Q0180 Dolasetron Mesylate Anzemet 100 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 Apr 1, 1998 In Use
Q5146 Trastuzumab-strf (hercessi) Hercessi 10mg Immunotherapy Monoclonal Antibody HER2 No 2025 Jan 1, 2025 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
J9382 Zenocutuzumab-zbco Bizengri 1mg Immunotherapy Monoclonal Antibody HER2, HER3 No 2024 Jul 9, 2025 In Use
J9227 Isatuximab-irtc Sarclisa 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 In Use
S0119 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan 1, 2012 In Use
J0893 Decitabine (Sun Pharma) Decitabine 1mg Chemotherapy Antimetabolite Pyrimidine Analog No 2014 Dec 21, 2022 In Use
J9321 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec 7, 2023 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
NA lenvatinib Lenvima 4 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET Yes 2015 In Use
J8510 Busulfan Myleran 2 mg Chemotherapy Alkylating Agent Alkylsulfonate Yes 1954 Jan 1, 2000 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERÉ‘ Yes 2023 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
Q0167 Dronabinol Marinol 2.5 mg Ancillary Therapy Antiemetic CB1/CB2 Yes 1985 Apr 1, 1998 In Use
J2405 Ondansetron Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1991 Jan 1, 1993 In Use
J9329 Tislelizumab-jsgr Tevimbra 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2024 Sep 11, 2024 In Use
NA Trilostane Modrastane 60 mg, 120 mg Hormonal Therapy Adrenocortical suppressant Yes 1984 1994 In Use
Q5158 Denosumab-bnht Bomyntra, Conexxence 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
J2277 Motixafortide Motixafortide 0.25mg Ancillary Therapy Immunostimulant Stem cell mobilizer No 2023 Apr 17, 2024 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.